Tradestie Institutional Equity Comparison Engine

CGEN vs ACRS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CGEN Overall Edge

CGEN Captures Institutional Edge (3โ€“1 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Compugen Ltd (CGEN) driven by superior Valuation, Growth & Margin, Momentum & Technical while ACRS counters with relative strength in Options & Structure. Fundamentally, CGEN trades at 12.4x Forward P/E with 41.3% operating margin (+102.1% YoY revenue) versus ACRS at N/M Forward P/E and -1412.4% operating margin (-55.1% YoY). In options structure, CGEN sits in BREAKDOWN (57th %ile IV; Dealer Gamma Walls on Pro) against ACRS sits in BREAKDOWN (1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CGEN
CGEN 12.4x vs ACRS N/M Fwd P/E
Growth & Margin Winner CGEN
Op Margin 41.3% vs -1412.4% ยท YoY +102.1% vs -55.1%
Momentum & Technical Winner CGEN
1Y +23.2% vs +34.1% ยท 52W Pos 33% vs 26%
Options & Structure Winner ACRS
BREAKDOWN (57th %ile IV) vs BREAKDOWN (1st %ile IV)
CGEN NASDAQ
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap $193.2M
1M Return +2.54%
1Y Return +23.17%
Forward P/E 12.4x
Unified AI Score
47.1 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 54.0 Mom 64.0
ACRS NASDAQ
Aclaris Therapeutics, Inc.
Pharmaceutical Preparations
$3.38
-6.24% 1D
Market Cap $548.0M
1M Return -2.87%
1Y Return +34.13%
Forward P/E N/M
Unified AI Score
44.7 / 100 HOLD
Tech 41.0 Fund 54.0 Flow 64.0 Mom 70.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CGEN +23.17% ACRS +34.13% Spread: +10.96 pp (ACRS Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CGEN Revenue ACRS Revenue CGEN Op. Margin ACRS Op. Margin Margin Edge
FY2018 $20M $10M -130.5% -1378.3% CGEN
FY2019 N/A $0M N/A -2627.3% ACRS
FY2020 $0M $10M -1574.8% -785.4% ACRS
FY2021 $10M $10M -584.6% -1327.1% CGEN
FY2022 $10M $30M -471.7% -302.0% ACRS
FY2023 $30M $30M -38.8% -311.6% CGEN
FY2024 $30M $20M -53.4% -758.2% CGEN
FY2025 $70M $10M 43.1% -975.9% CGEN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CGEN (9) vs ACRS (1)
Institutional Metric CGEN ACRS Criterion Row Winner
Market Capitalization Scale $193.2M $548.0M Larger Scale ACRS
Trailing P/E Ratio Valuation 5.2x N/M Lower Multiple CGEN
Forward P/E Ratio Valuation 12.4x N/M Lower Multiple CGEN
Revenue Growth (YoY) Growth +102.1% -55.1% Higher Growth CGEN
Operating Margin (TTM) Profitability 41.3% -1412.4% Higher Margin CGEN
Net Profit Margin Profitability 47.9% 0.0% Higher Margin CGEN
Return on Equity (ROE) Capital Efficiency 57.2% -55.5% Higher ROE CGEN
52-Week Range Position Momentum 33% ($1โ€“$3) 26% ($2โ€“$7) Stronger Trend CGEN
Beta / 30D Volatility Risk Regime 1.44ฮฒ ยท 62% Vol 1.57ฮฒ ยท 75% Vol Lower Realized Risk CGEN
Unified Institutional Score Composite Signal 47.1 / 100 (HOLD) 44.7 / 100 (HOLD) Higher Composite CGEN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CGEN vs ACRS Buy Guide
CGEN BREAKDOWN
143d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 57th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CGEN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ACRS BREAKDOWN
130d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 1st %ile
IV Regime Compressed (<25th %ile)
Live ACRS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CGEN nor ACRS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.